Genscript Biotech (HK:1548)
:1548
Want to see HK:1548 full AI Analyst Report?
1548 Stock Chart & Stats
HK$13.76
-HK$0.07(-0.74%)
At close: 4:00 PM EST
HK$13.76
-HK$0.07(-0.74%)
Day’s Range― - ―
52-Week RangeHK$10.36 - HK$19.40
Previous CloseN/A
Volume5.33M
Average Volume (3M)11.61M
Market Cap
HK$29.22B
Enterprise ValueHK$4.16B
Total Cash (Recent Filing)HK$843.01M
Total Debt (Recent Filing)HK$523.15M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding2,188,417,200
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.05Price Target Upside38.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$813.83M
Bulls Say, Bears Say
Bulls Say
Strong Revenue RecoveryA 74% revenue rebound in 2025 signals durable demand recovery across research and CDMO services. Sustained top-line growth supports fixed-cost absorption, enables reinvestment in capacity and R&D, and improves the company's ability to convert platform breadth into recurring contracted work over months.
Healthy Operating MarginsHigh gross and EBIT margins indicate structural pricing power and operational leverage in higher-value services like biologics CDMO and antibody development. Durable margin profiles support cash generation and competitive reinvestment, making earnings from core operations more resilient if revenue holds.
Improved Cash Generation & Manageable LeverageReturn to positive operating and free cash flow plus a low debt-to-equity ratio gives the company financial flexibility to fund capex, scale GMP capacity, and weather development timing risk. Strong cash generation reduces reliance on external financing over the medium term.
Bears Say
Earnings VolatilityExtreme year-to-year swings in net income undermine predictability of core profitability. Such volatility may reflect non-recurring items, timing of milestone revenue, or accounting swings tied to subsidiaries, making it hard to forecast sustainable earnings and plan capacity or shareholder returns.
Inconsistent Cash Flow HistoryPrior multi-year cash burn followed by a single-year improvement suggests cash generation is cyclical and not yet structural. Inconsistent free cash flow raises risk that investments or working capital shocks could re-introduce funding needs, constraining long-term capital allocation decisions.
Revenue Lumpy From Client Timelines & Subsidiary ExposureBusiness depends on timing of client R&D progress and contributions from subsidiaries, producing lumpy project revenue. This structural dependency makes capacity utilization and backlog unpredictable and can convert operational wins into uneven financial outcomes across quarters.
Genscript Biotech News
1548 FAQ
What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$10.36 and its highest was HK$19.40 in the past 12 months.
What is Genscript Biotech’s market cap?
Genscript Biotech’s market cap is HK$29.22B.
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Mar 16, 2026. The company reported -HK$1.801 earnings per share for the quarter, missing the consensus estimate of -HK$0.235 by -HK$1.566.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Undervalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a Notavailable dividend of HK$0.012 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is -0.08.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,188,417,200 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -HK$1.801 in its last earnings report, missing expectations of -HK$0.235. Following the earnings report the stock price went up 1.262%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in HK:1548
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genscript Biotech Stock Smart Score
Company Description
Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
1548 Company Deck
1548 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.View all HK:1548 earnings summaries1548 Stock 12 Month Forecast
Average Price Target
HK$19.05
▲(38.42% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---